Pharmaceutical Business Review
Return to: PBR Home

News

View news from other Pharmaceutical sectors:
61-75 of 51311 results
Beactica signs three-year extension of master services deal with Sanofi
Swedish drug discovery company Beactica has entered into a three-year extension of its master services agreement with Sanofi.
Production & Manufacturing > Manufacturing > News
AstraZeneca’s Imfinzi extends survival rate in lung cancer patients
By PBR Staff Writer
AstraZeneca’s oncology immunotherapy Imfinzi (durvalumab) met the second primary endpoint of overall survival in the phase III trial for unresectable stage III non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
EC approves Sandoz' Zessly to treat gastroenterological, rheumatological and dermatological diseases
Sandoz has secured approval from the European Commission for Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.
News
Malvern Panalytical unveils Zetasizer Pro and Ultra systems
Malvern Panalytical has launched its new Zetasizer Pro and Ultra systems, designed to help in decision-making within crucial analytical workflows associated to product development and quality control.
Production & Manufacturing > Process & Production > News
BioMarin’s Palynziq gets FDA approval to treat adults with phenylketonuria
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved BioMarin Pharmaceutical’s Palynziq (pegvaliase-pqpz) Injection for the treatment of adults with phenylketonuria (PKU), a serious genetic disease.
Regulatory Affairs > News
FDA declines to approve Cosmo’s NDA for Methylene Blue MMX
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Cosmo Pharmaceuticals, saying that it cannot approve the latter’s Methylene Blue MMX as a visualization aid to increase detection of lesions in the colon.
Regulatory Affairs > News
Epigen to license LPA1 receptor small molecule program to Novo Nordisk
Epigen Biosciences has entered into a collaboration agreement with Novo Nordisk, under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease and other chronic diseases associated with metabolic syndrome.
Drug Research > Drug Discovery & Development > News
Cara out-licenses Korsuva injection ex-US rights to Vifor Fresenius for $520m
By PBR Staff Writer
Cara Therapeutics has granted licensing worldwide rights with the exception of the US, Japan and South Korea to commercialize its Korsuva (CR845/difelikefalin) injection to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
Drug Research > Drug Discovery & Development > News
Takeda to sell Techpool to Chinese JV partners
Takeda Pharmaceutical has agreed to divest its its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma (Techpool), a China-based firm focused on urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care, to its joint venture (JV) partners for $280m.
Production & Manufacturing > Manufacturing > News
FDA to review Zynquista as potential treatment for type 1 diabetes
The US Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin).
Regulatory Affairs > News
WuXi Biologics to establish $60m biologics manufacturing facility in Singapore
By PBR Staff Writer
Chinese firm WuXi Biologics has announced a S$80m ($60m) investment to set up an a biologics manufacturing facility in Singapore.
Production & Manufacturing > Manufacturing > News
Evotec and Celgene partner to develop oncology treatments
By PBR Staff Writer
Germany-based drug discovery firm Evotec has partnered with American biotechnology company Celgene to identify new therapeutics in oncology with an initial focus on solid tumors.
Drug Research > Drug Discovery & Development > News
Alivio Therapeutics secures two US patents for inflammation-targeting technology platform
Alivio Therapeutics, an affiliate of PureTech Health, announced that the US Patent and Trademark Office (USPTO) issued U.S. Patent Nos. 9,962,339 and 9,974,859, related to its inflammation-targeting technology platform.
Drug Research > Drug Discovery & Development > News
ViiV Healthcare gets EC approval for Juluca to treat HIV-1 infection
By PBR Staff Writer
ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has secured marketing approval from the European Commission (EC) for Juluca (dolutegravir 50mg/rilpivirine 25mg) to treat human immunodeficiency virus type 1 (HIV-1) infection.
Regulatory Affairs > News
Midatech begins dosing in first human trial of cancer drug Q-Octreotide
Midatech has commenced initial dosing in the first in-human study of its sustained release product Q-Octreotide (MTD201) for the treatment of carcinoid cancer and acromegaly.
Contract Research & Services > Clinical Trials > News
61-75 of 51311 results